BIVI (BioVie Inc.) קצב צמיחת רווח למניה בשנה הנוכחית

BioVie Inc. develops innovative therapies for severe liver pathologies and neurodegeneration. The annual earnings per share growth vector on the GURU.Markets chart confirms a trend where the value has stabilized at 0.00. However, the expansion of Alzheimer's and Parkinson's disease programs is increasing laboratory expenses. The brand's high scientific authority and the trust of clinics ensure the company maintains a stable position.

BioVie Inc. focuses on the development of the innovative drug NE3107 to combat neuroinflammation in Alzheimer's and Parkinson's diseases. The commercialization efficiency of such developments directly impacts the net profit distributed per share. This metric measures the percentage deviation of the current EPS from the value of the same period last year. It allows for an assessment of the business's financial resilience to market shocks. By analyzing the shift in earnings per share compared to last year, an investor determines the company's profitability dynamics.